NAD+ acts as a coenzyme for most redox reactions in metabolic pathways, helping to properly regulate oxidative stress and prevent aging. Furthermore, SIRT and PARP enzymes, which are essential for various biological processes, are NAD+-consuming enzymes. Maintaining NAD+ levels is essential because NAD+ declines with age, and impaired NAD+ metabolism (where NAD+ is consumed by SIRT and PARP enzyme activity) can contribute to various age-related diseases.

NMN has been shown to act as an NAD+ booster in various animal models of age-related diseases. Numerous preclinical studies have shown that oral administration of NMN can help prevent declines in NAD+ levels in the body, contributing to anti-aging. In 2020, the first clinical trial evaluated the safety of a single oral dose of NMN. Because early clinical trial reports were not as diverse as preclinical studies , many may have worried about long-term side effects from NMN . Nevertheless, we would like to share the clinical trial results with the many consumers who have trusted Rocket America and taken NMN consistently for over 4 years.

In the study below, we will evaluate the effects of 12 weeks of NMN supplementation on metabolic health parameters, including blood NAD+ metabolite levels, SIRT1 expression, and CVD risk factors.

Figure 1. Clinical trial flow chart

A total of 36 healthy men and women aged 40–59 years participated in this study , and the subjects were randomly assigned to either the NMN intake group (250 mg/day) or the placebo group. No subjects were excluded during the eligibility assessment phase , and the baseline characteristics of the participants are reported in Table 1 below.

Table 1. Baseline characteristics of study participants (mean ± standard deviation)

Each parameter was measured before the intervention began, and no significant differences were found between participants at baseline. After 12 weeks of intervention, one participant in each group was lost to follow-up and was considered a dropout (Figure 1).

Table 2. Body composition and metabolic parameters (mean ± standard deviation) of the placebo and NMN groups before and after the intervention period.

All subjects who completed the study showed no significant changes in hematology, clinical chemistry, and hormones after 12 weeks of intervention (Table 2), suggesting that long-term NMN supplementation at 250 mg/day is safe and well-tolerated in healthy middle-aged adults .

Table 3. NAD+ metabolites (mean ± standard deviation) in the placebo and NMN intake groups before and after the intervention period.

Subsequently, serum NAM in the NMN group significantly increased after 12 weeks (p=0.006) , whereas serum NAM in the placebo group significantly decreased after 12 weeks ( p=0.014). Enzymes that consume NAD+, such as SIRT and PARD enzymes, hydrolyze NAD+ to produce NAM and ADPR products.

That is, the increase in NAM levels suggests that NMN effectively improved NAD+ metabolism in middle-aged adults.

In conclusion, long-term NMN supplementation at 250 mg/day was well tolerated and did not cause side effects.

It has been shown to safely and effectively increase NAD+ metabolism in healthy middle-aged adults.

Next, we will continue to introduce papers on the efficacy of long-term use of NMN.

Let's understand together the second part of the same study on long-term use of NMN, <The effect of NMN supplementation according to vascular condition> .

Click on the photo to go to the next part!

[References and Figure Source]

1) Nicotinamide adenine dinucleotide metabolism and arterial stiffness after long-term nicotinamide mononucleotide supplementation: a randomized, double-blind, placebo-controlled trial

© All rights reserved to Rocket America. Any unauthorized use is prohibited.

#nmnsideeffects #nmnlong-term #nmnclinical #nmnnutritionalsupplements #nmnefficacy #nmncardiovasculardisease